Literature DB >> 18629655

Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) regulate murine neural progenitor cell survival, proliferation, and differentiation.

Eugene Scharf1, Victor May, Karen M Braas, Kristin C Shutz, Yang Mao-Draayer.   

Abstract

Neural stem/progenitor cells (NPC) have gained wide interest over the last decade from their therapeutic potential, either through transplantation or endogenous replacement, after central nervous system (CNS) disease and damage. Whereas several growth factors and cytokines have been shown to promote NPC survival, proliferation, or differentiation, the identification of other regulators will provide much needed options for NPC self-renewal or lineage development. Although previous studies have shown that pituitary adenylate cyclase-activating polypeptide (PACAP)/vasoactive intestinal peptide (VIP) can regulate stem/progenitor cells, the responses appeared variable. To examine the direct roles of these peptides in NPCs, postnatal mouse NPC cultures were withdrawn from epidermal growth factor (EGF) and fibroblastic growth factor (FGF) and maintained under serum-free conditions in the presence or absence of PACAP27, PACAP38, or VIP. The NPCs expressed the PAC1(short)null receptor isoform, and the activation of these receptors decreased progenitor cell apoptosis more than 80% from TUNEL assays and facilitated proliferation more than fivefold from bromodeoxyuridine (BrdU) analyses. To evaluate cellular differentiation, replicate control and peptide-treated cultures were examined for cell fate marker protein and transcript expression. In contrast with previous work, PACAP peptides downregulated NPC differentiation, which appeared consistent with the proliferation status of the treated cells. Accordingly, these results demonstrate that PACAP signaling is trophic and can maintain NPCs in a multipotent state. With these attributes, PACAP may be able to promote endogenous NPC self-renewal in the adult CNS, which may be important for endogenous self-repair in disease and ageing processes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629655      PMCID: PMC2724758          DOI: 10.1007/s12031-008-9097-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  55 in total

1.  Opposing mitogenic regulation by PACAP in sympathetic and cerebral cortical precursors correlates with differential expression of PACAP receptor (PAC1-R) isoforms.

Authors:  N Lu; R Zhou; E DiCicco-Bloom
Journal:  J Neurosci Res       Date:  1998-09-15       Impact factor: 4.164

2.  Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway.

Authors:  D Vaudry; B J Gonzalez; M Basille; Y Anouar; A Fournier; H Vaudry
Journal:  Neuroscience       Date:  1998-06       Impact factor: 3.590

3.  Pituitary adenylate cyclase-activating polypeptide (PACAP) protects dorsal root ganglion neurons from death and induces calcitonin gene-related peptide (CGRP) immunoreactivity in vitro.

Authors:  M Lioudyno; Y Skoglösa; N Takei; D Lindholm
Journal:  J Neurosci Res       Date:  1998-01-15       Impact factor: 4.164

4.  Neuronal protection from apoptosis by pituitary adenylate cyclase-activating polypeptide.

Authors:  J Tanaka; K Koshimura; Y Murakami; M Sohmiya; N Yanaihara; Y Kato
Journal:  Regul Pept       Date:  1997-09-26

5.  Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells.

Authors:  N Lu; E DiCicco-Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

6.  Pituitary adenylyl cyclase-activating polypeptide and nerve growth factor use the proteasome to rescue nerve growth factor-deprived sympathetic neurons cultured from chick embryos.

Authors:  D A Przywara; J S Kulkarni; T D Wakade; D V Leontiev; A R Wakade
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

7.  Novel stable PACAP analogs with potent activity towards the PAC1 receptor.

Authors:  Steve Bourgault; David Vaudry; Béatrice Botia; Alain Couvineau; Marc Laburthe; Hubert Vaudry; Alain Fournier
Journal:  Peptides       Date:  2008-02-13       Impact factor: 3.750

8.  Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons.

Authors:  N Takei; Y Skoglösa; D Lindholm
Journal:  J Neurosci Res       Date:  1998-12-01       Impact factor: 4.164

9.  Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis.

Authors:  J A Waschek; R A Casillas; T B Nguyen; E M DiCicco-Bloom; E M Carpenter; W I Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 10.  Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.

Authors:  A Arimura
Journal:  Jpn J Physiol       Date:  1998-10
View more
  12 in total

1.  Pituitary adenylate cyclase-activating polypeptide is protective against oxidative stress in human retinal pigment epithelial cells.

Authors:  Laszlo Mester; Krisztina Kovacs; Boglarka Racz; Izabella Solti; Tamas Atlasz; Krisztina Szabadfi; Andrea Tamas; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2010-07-20       Impact factor: 3.444

2.  Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion.

Authors:  Gabriella Horvath; Boglarka Racz; Dora Reglodi; Krisztina Kovacs; Peter Kiss; Ferenc Gallyas; Zita Bognar; Aliz Szabo; Tamas Magyarlaki; Eszter Laszlo; Andrea Lubics; Andrea Tamas; Gabor Toth; Peter Szakaly
Journal:  J Mol Neurosci       Date:  2010-03-16       Impact factor: 3.444

3.  Protein kinase A-dependent substance P expression by pituitary adenylate cyclase-activating polypeptide in rat sensory neuronal cell line ND7/23 cells.

Authors:  Atsuko Inoue; Masatoshi Ohnishi; Chiharu Fukutomi; Miho Kanoh; Mutsumi Miyauchi; Takashi Takata; Daiju Tsuchiya; Hiroaki Nishio
Journal:  J Mol Neurosci       Date:  2012-03-15       Impact factor: 3.444

4.  Sitagliptin protects proliferation of neural progenitor cells in diabetic mice.

Authors:  Tomás P Bachor; Melisa D Marquioni-Ramella; Angela M Suburo
Journal:  Metab Brain Dis       Date:  2015-02-20       Impact factor: 3.584

5.  PACAP modulation of calcium ion activity in developing granule cells of the neonatal mouse olfactory bulb.

Authors:  Mavis Irwin; Ann Greig; Petr Tvrdik; Mary T Lucero
Journal:  J Neurophysiol       Date:  2014-12-04       Impact factor: 2.714

6.  Interferon-gamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells.

Authors:  Johanna Mäkelä; Raili Koivuniemi; Laura Korhonen; Dan Lindholm
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

7.  Pro- and anti-mitogenic actions of pituitary adenylate cyclase-activating polypeptide in developing cerebral cortex: potential mediation by developmental switch of PAC1 receptor mRNA isoforms.

Authors:  Yan Yan; Xiaofeng Zhou; Zui Pan; Jianjie Ma; James A Waschek; Emanuel DiCicco-Bloom
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

Review 8.  Regulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potential.

Authors:  He Huang; Hu Wang; Maria E Figueiredo-Pereira
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

9.  Maxadilan prevents apoptosis in iPS cells and shows no effects on the pluripotent state or karyotype.

Authors:  Zhiyi Zhao; Rongjie Yu; Jiayin Yang; Xiaofei Liu; Meihua Tan; Hongyang Li; Jiansu Chen
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

10.  Corticotropin-releasing hormone exerts direct effects on neuronal progenitor cells: implications for neuroprotection.

Authors:  Y Koutmani; P K Politis; M Elkouris; G Agrogiannis; M Kemerli; E Patsouris; E Remboutsika; K P Karalis
Journal:  Mol Psychiatry       Date:  2013-02-05       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.